Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II SOXIRI first-line study in unresectable or metastatic pancreatic cancer
ChiCTR1800018233Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, oxaliplatin and irinotecan in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: objective response rate. Started Aug 2018; status: recruiting.
02
Drugs
tegafuroxaliplatinirinotecan
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR1800018233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018233.